Dutasteride: A Review of its Use in the Management of Prostate Disorders | Zendy

Garrett Pohlman | Zendy; Emily A. Pohlman | Zendy; E. David Crawford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dutasteride: A Review of its Use in the Management of Prostate Disorders

Author(s) -

Garrett Pohlman,

Emily A. Pohlman,

E. David Crawford

Publication year - 2011

Publication title -

clinical medicine insights therapeutics

Language(s) - English

Resource type - Journals

ISSN - 1179-559X

DOI - 10.4137/cmt.s1956

Subject(s) - dutasteride , tamsulosin , medicine , urology , finasteride , prostate cancer , hyperplasia , placebo , lower urinary tract symptoms , prostate , 5 alpha reductase inhibitor , urinary retention , cancer , alternative medicine , pathology

Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes approved for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) who have an enlarged prostate. It has been demonstrated to be effective as monotherapy, or in combination with the alpha-adrenergic antagonist (a-blocker), tamsulosin, in several randomized, double-blind, placebo controlled trials and their open-label extensions. Treatment with dutasteride is generally safe and well tolerated. Dutasteride has become established in the management of men with lower urinary tract symptoms (LUTS) and reduces the risk of acute urinary retention and surgery related to BPH. Dutasteride may also have a role as a chemopreventive agent in the future as emerging evidence demonstrates a reduced risk of prostate cancer with this agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research